Clinical Trial Update: Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1 [Phase 1]

View source ↗

Summary

Phase 1 trial update evaluating NY-ESO-1–targeted gene-modified T cells combined with NY-ESO-1 vaccine therapy and nivolumab in patients with stage IV or locall…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Solid Tumors

Drugs mentioned

• NY-ESO-1 vaccine
• NY-ESO-1–targeted gene-modified T cells
• nivolumab (nivolumab)

Snippet

Sponsor: Jonsson Comprehensive Cancer Center | Conditions: Adult Solid Neoplasm, Childhood Solid Neoplasm | Phase 1 | Status: COMPLETED